Patents by Inventor William A. Gahl
William A. Gahl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11155521Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CB1 receptor mediating scaffold and (ii) a second therapeutic scaffold.Type: GrantFiled: March 4, 2016Date of Patent: October 26, 2021Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Resat Cinar, George Kunos, Malliga R. Iyer, William A. Gahl, Bernadette R. Gochuico, May Christine Vergara Malicdan
-
Patent number: 10953026Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.Type: GrantFiled: May 20, 2019Date of Patent: March 23, 2021Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk
-
Publication number: 20190374561Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.Type: ApplicationFiled: May 20, 2019Publication date: December 12, 2019Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicInventors: Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk
-
Patent number: 10335426Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.Type: GrantFiled: September 12, 2017Date of Patent: July 2, 2019Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesInventors: Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk
-
Publication number: 20180117072Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.Type: ApplicationFiled: September 12, 2017Publication date: May 3, 2018Applicant: The United States of America, as represented by the Secretary, Department of Health and HumanInventors: Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk
-
Publication number: 20160257654Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CB1 receptor mediating scaffold and (ii) a second therapeutic scaffold.Type: ApplicationFiled: March 4, 2016Publication date: September 8, 2016Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Resat Cinar, George Kunos, Malliga R. Iyer, William A. Gahl, Bernadette R. Gochuico, May Christine Vergara Malicdan
-
Patent number: 9364448Abstract: A method is provided for the treatment of vision problems in a subject suffering from one of various forms of albinism, including, for example, oculocutaneous albinism types OCA1a and OCA1b, as well as ocular albinism type 1, resulting from mutations in the GPR143 gene, as well as the OCA2, OCA3 or OCA4 genes, by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the compound (2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione), also known as NTBC for a sufficient period of time. The administration of NTBC is believed to increase the amount of pigmentation in the subject and alleviate certain symptoms caused by lack of pigmentation in the eye tissues. Also described are methods of use of NTBC for increasing the pigmentation of a subject for cosmetic purposes, by administering to the subject a therapeutically effective amount of NTBC.Type: GrantFiled: August 28, 2014Date of Patent: June 14, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Brian P. Brooks, William A. Gahl
-
Patent number: 9341619Abstract: Methods are disclosed for diagnosing a hyposialylation disorder. Methods are also disclosed for determining the effectiveness of a therapeutic agent for treatment of a hyposialylation disorder in a subject. These methods include measuring an amount of monosialylated Thomsen-Friedenreich (ST) antigen and measuring an amount of non-sialylated Thomsen-Friedenreich antigen (T) in a biological sample, such as a serum or plasma sample from the subject and determining the ratio of T to ST. A ratio of T to monosialylated ST of about 0.06 or higher diagnoses the hyposialylation disorder or indicates that the therapeutic agent is not effective for the treatment of the hyposialylation disorder. In other embodiments, a ratio of T to ST less than about 0.06 indicates that the therapeutic agent is effective for the treatment of the hyposialylation disorder, or the subject does not have the hyposialylation disorder.Type: GrantFiled: March 13, 2014Date of Patent: May 17, 2016Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Emory UniversityInventors: Marjan Huizing, William A. Gahl, Nuria Carrillo-Carrasco, Miao He, Xueli Li, Rong Jiang
-
Publication number: 20160025717Abstract: Methods are disclosed for diagnosing a hyposialylation disorder. Methods are also disclosed for determining the effectiveness of a therapeutic agent for treatment of a hyposialylation disorder in a subject. These methods include measuring an amount of monosialylated Thomsen-Friedenreich (ST) antigen and measuring an amount of non-sialylated Thomsen-Friedenreich antigen (T) in a biological sample, such as a serum or plasma sample from the subject, and determining the ratio of T to ST.Type: ApplicationFiled: March 13, 2014Publication date: January 28, 2016Applicants: EMORY UNIVERSITY, THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv, Emory UniversityInventors: Marjan Huizing, William A. Gahl, Nuria Carrillo-Carrasco, Miao He, Xueli Li, Rong Jiang
-
Publication number: 20150290229Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.Type: ApplicationFiled: June 29, 2015Publication date: October 15, 2015Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk
-
Patent number: 9095597Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.Type: GrantFiled: March 8, 2013Date of Patent: August 4, 2015Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk
-
Publication number: 20140371325Abstract: A method is provided for the treatment of vision problems in a subject suffering from one of various forms of albinism, including, for example, oculocutaneous albinism types OCA1a and OCA1b, as well as ocular albinism type 1, resulting from mutations in the GPR143 gene, as well as the OCA2, OCA3 or OCA4 genes, by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the compound (2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione), also known as NTBC for a sufficient period of time. The administration of NTBC is believed to increase the amount of pigmentation in the subject and alleviate certain symptoms caused by lack of pigmentation in the eye tissues. Also described are methods of use of NTBC for increasing the pigmentation of a subject for cosmetic purposes, by administering to the subject a therapeutically effective amount of NTBC.Type: ApplicationFiled: August 28, 2014Publication date: December 18, 2014Inventors: Brian P. Brooks, William A. Gahl
-
Publication number: 20140271615Abstract: Methods are disclosed for diagnosing a hyposialylation disorder. Methods are also disclosed for determining the effectiveness of a therapeutic agent for treatment of a hyposialylation disorder in a subject. These methods include measuring an amount of monosialylated Thomsen-Friedenreich (ST) antigen and measuring an amount of non-sialylated Thomsen-Friedenreich antigen (T) in a biological sample, such as a serum or plasma sample from the subject and determining the ratio of T to ST. A ratio of T to monosialylated ST of about 0.06 or higher diagnoses the hyposialylation disorder or indicates that the therapeutic agent is not effective for the treatment of the hyposialylation disorder. In other embodiments, a ratio of T to ST less than about 0.06 indicates that the therapeutic agent is effective for the treatment of the hyposialylation disorder, or the subject does not have the hyposialylation disorder.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicants: EMORY UNIVERSITY, THE UNITED STATES OF AMERICA, as represented by the Secretary,Department of Health and Human ServcInventors: Marjan Huizing, William A. Gahl, Nuria Carrillo-Carrasco, Miao He, Xueli Li, Rong Jiang
-
Patent number: 8822540Abstract: A method is provided for the treatment of vision problems in a subject suffering from one of various forms of albinism, including, for example, oculocutaneous albinism types OCA1a and OCA1b, as well as ocular albinism type 1, resulting from mutations in the GPR143 gene, as well as the OCA2, OCA3 or OCA4 genes, by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the compound (2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione), also known as NTBC for a sufficient period of time. The administration of NTBC is believed to increase the amount of pigmentation in the subject and alleviate certain symptoms caused by lack of pigmentation in the eye tissues. Also described are methods of use of NTBC for increasing the pigmentation of a subject for cosmetic purposes, by administering to the subject a therapeutically effective amount of NTBC.Type: GrantFiled: February 25, 2011Date of Patent: September 2, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Brian P. Brooks, William A. Gahl
-
Publication number: 20130109645Abstract: Disclosed are a method of treating or preventing a disorder in a mammal comprising administering to the mammal an adenosine receptor agonist or an adenosine receptor antagonist, either alone or in combination, in an amount effective to treat or prevent medial vascular or joint capsule calcification. Disclosed are methods of detecting or diagnosing a vascular or joint capsule calcification disorder, as well as a nucleic acid comprising a mutation in one or more exons of human NT5E selected from the group consisting of Exon 3, Exon 5, and Exon 9.Type: ApplicationFiled: March 30, 2011Publication date: May 2, 2013Applicant: The united States of America,as represented by Secretary,Dept.,of Health and Human ServicesInventors: William A. Gahl, Manfred Boehm, Cynthia St. Hilaire, Shira G. Ziegler, Thomas C. Markello
-
Patent number: 8410063Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.Type: GrantFiled: May 30, 2008Date of Patent: April 2, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk
-
Publication number: 20130058998Abstract: A method for treating a disorder characterized by hyposialylation in a subject that includes administering to the subject an effective amount of (i) a composition comprising N-acetylmannosamine, or a derivative thereof, encapsulated within a liposome, or (ii) a composition comprising N-acetylneuraminic acid, or a derivative thereof, encapsulated within a liposome, wherein the liposome comprises 1,2-dioleoyl-3-trimethylammonium-propane and cholesterol.Type: ApplicationFiled: September 6, 2012Publication date: March 7, 2013Inventors: Marjan Huizing, Tal Yardeni, Christopher M. Jay, Nancy Smyth Templeton, William A. Gahl
-
Publication number: 20120322887Abstract: A method is provided for the treatment of vision problems in a subject suffering from one of various forms of albinism, including, for example, oculocutaneous albinism types OCA1a and OCA1b, as well as ocular albinism type 1, resulting from mutations in the GPR143 gene, as well as the OCA2, OCA3 or OCA4 genes, by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the compound (242-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione), also known as NTBC for a sufficient period of time. The administration of NTBC is believed to increase the amount of pigmentation in the subject and alleviate certain symptoms caused by lack of pigmentation in the eye tissues. Also described are methods of use of NTBC for increasing the pigmentation of a subject for cosmetic purposes, by administering to the subject a therapeutically effective amount of NTBC.Type: ApplicationFiled: February 25, 2011Publication date: December 20, 2012Applicant: The U. S. of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Brian P. Brooks, William A. Gahl
-
Publication number: 20100249047Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.Type: ApplicationFiled: May 30, 2008Publication date: September 30, 2010Inventors: Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk